4,658 Shares in Tempus AI, Inc. $TEM Purchased by MetLife Investment Management LLC

Key Points

• MetLife Investment Management LLC purchased a new stake in Tempus AI, acquiring 4,658 shares valued at approximately $225,000 in the first quarter.
• Tempus AI reported a quarterly revenue of $314.64 million, exceeding analyst estimates and reflecting an 89.5% increase compared to the same quarter last year.
• Insider activity revealed significant sales, with executives selling a combined total of 903,104 shares valued at $63,733,330 over the last ninety days.

MetLife Investment Management LLC purchased a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 4,658 shares of the company's stock, valued at approximately $225,000.

A number of other institutional investors also recently modified their holdings of TEM. ARK Investment Management LLC boosted its holdings in Tempus AI by 35.9% in the 1st quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company's stock valued at $361,867,000 after purchasing an additional 1,981,755 shares during the period. Vanguard Group Inc. boosted its holdings in Tempus AI by 6,247.5% in the 1st quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company's stock valued at $289,204,000 after purchasing an additional 5,900,668 shares during the period. Nikko Asset Management Americas Inc. boosted its holdings in Tempus AI by 31.5% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company's stock valued at $205,401,000 after purchasing an additional 1,021,460 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Tempus AI by 31.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock valued at $205,284,000 after purchasing an additional 1,016,384 shares during the period. Finally, CloudAlpha Capital Management Limited Hong Kong bought a new position in Tempus AI in the 1st quarter valued at $34,119,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Bank of America raised their price objective on shares of Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a research report on Wednesday, June 25th. Needham & Company LLC restated a "buy" rating and set a $70.00 price objective on shares of Tempus AI in a research report on Friday, August 8th. HC Wainwright raised their price objective on shares of Tempus AI from $90.00 to $98.00 and gave the company a "buy" rating in a research report on Friday. Guggenheim raised their price objective on shares of Tempus AI from $65.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, June 30th. Finally, Morgan Stanley raised their price objective on shares of Tempus AI from $65.00 to $68.00 and gave the company an "overweight" rating in a research report on Tuesday, August 12th. Seven investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $70.17.

Tempus AI Trading Down 2.7%

NASDAQ:TEM traded down $2.40 during trading hours on Friday, reaching $86.38. The company's stock had a trading volume of 6,728,445 shares, compared to its average volume of 10,232,446. The firm has a market capitalization of $15.01 billion, a price-to-earnings ratio of -72.59 and a beta of 5.08. The firm has a 50-day simple moving average of $67.61 and a 200-day simple moving average of $59.59. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $91.45. The company has a debt-to-equity ratio of 2.58, a quick ratio of 1.43 and a current ratio of 1.54.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. The company had revenue of $314.64 million for the quarter, compared to analysts' expectations of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The firm's revenue was up 89.5% compared to the same quarter last year. During the same quarter last year, the company earned ($6.86) EPS. Tempus AI has set its FY 2025 guidance at EPS. Research analysts expect that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other Tempus AI news, CEO Eric P. Lefkofsky sold 332,500 shares of the firm's stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $74.10, for a total value of $24,638,250.00. Following the sale, the chief executive officer owned 9,207,533 shares of the company's stock, valued at $682,278,195.30. This trade represents a 3.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Ryan M. Bartolucci sold 1,904 shares of the firm's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total transaction of $142,133.60. Following the completion of the sale, the chief accounting officer directly owned 45,895 shares in the company, valued at approximately $3,426,061.75. This trade represents a 3.98% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 903,104 shares of company stock worth $63,733,330. 26.27% of the stock is currently owned by insiders.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.